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Background. Constrained acetabular devices were developed to prevent dislocations after total 24 hip arthroplasty (THA). However, the data on their success has been contradictory. In this study 25 we aimed to assess implant survival of the constrained acetabular device in primary THA based 26 on the Finnish Arthroplasty Register data. 27
Methods. 373 primary THAs with constrained acetabular devices inserted from 2006 to 2017 28 were included. A reference group was formed on a 1:3 basis and matched for age, sex and 29 diagnosis, consisting of 1,118 conventional THAs. Implant survival estimates using death as 30 competing risk were assessed with revision for any reason and for any aseptic reason as the 31 endpoints. The Cox multiple regression models were adjusted by age, sex and diagnosis. Mean 32 follow-up time was 3.3 (0-12.4) years for the constrained device group and 3.8 (0-12.0) years 33 for the reference group. 34
Results. Overall, there were 21 revisions in the constrained device group and 49 in the reference 35 group. The 8-year survivorship for any reason was 94% (CI 91-96) for the constrained device 36 group and 93% (CI 89-97) for the reference group. With revision for any aseptic reason as the 37
Introduction 47 Dislocation is one of the most common reasons for revision surgery after primary total hip 48 arthroplasty (THA), covering 17-21% of all first-time revisions [1, 2] . The dislocation incidence 49 during the first postoperative year after primary THA varies from 2% to 4% [3] [4] [5] . Both patient-50 related and surgical factors such as posterior approach, poor component positioning, small 51 femoral head size, poor repair of soft-tissues and implant choice may predispose to THA 52 dislocation [3, 4, [6] [7] [8] . As the outcome after revision THA is generally poorer than after primary 53 THA and the complication rate is higher, it is important to prevent first-time dislocations. 54 Implant choice is one of the critical steps in preventing unstable THA. Currently, the 55 three main options available that provide some protection against dislocation are dual mobility 56 implants, large diameter femoral heads, and constrained acetabular devices. Despite some 57 variability in the data on the ability of constrained acetabular devices to prevent dislocation and 58 restore stability to prevent recurrent dislocation, they have become a generally accepted option 59 worldwide for treating instability in revision THA [9-11]. However, the role of constrained cups 60 in primary THA in preventing dislocations in high risk patients has not been settled. Despite their 61 advantages in terms of stability, constrained devices may result in a restricted range of motion 62 and have a greater prevalence of impingement of the femoral neck on the cup. Impingement is 63 responsible for high stress transmission to multiple interfaces, leading to liner damage, locking 64 mechanism failure, dislocation and loosening [10] . Therefore, the constrained acetabular device 65 system is intended only for special situations where the patient has a high risk of dislocation due 66 to a previous history of dislocation, severe joint laxity, palsy of the surrounding musculature or 67 abductor muscle deficiency. 68
The purpose of this study was to assess the revision rate associated with the constrained 69 acetabular device in primary THA and to compare it with a conventional THA reference group 70 with (1) revision for any reason, (2) revision for dislocation, (3) revision for any aseptic reason 71 and (4) revision for infection as the endpoints, based on data from the Finnish Arthroplasty 72
Register. 73 74
Patients and Methods 75
This study is based on data from the Finnish Arthroplasty Register (FAR), which covers most of 76 the total hip implants performed in Finland since 1980 [12] . Orthopedic units are obligated to 77 provide all the information essential for maintenance of the register to the Finnish National 78
Institute for Health and Welfare. In Finland, the data completeness for primary THA is > 95% 79 and for revision THA 81% [2] . Dates of death are obtained from the Population Information 80 System maintained by the Population Register Centre. Since May 2014, implant identification 81 has been performed using electronic scanning of reference codes in operating theatres, and the 82 operative information is then sent electronically to the register [2] . 83
84

Study device 85
The Freedom TM (ZimmerBiomet, Warsaw, IN, USA) constrained acetabular device system was 86 introduced in Finland in 2006 and is currently the most commonly used constrained device in the 87 country. It incorporates an equatorial flat section at 15° to the vertical axis along the sides of the 88 constrained liner, and a modular chrome-cobalt head which is always 36 mm in diameter ( Figure  89 1-A). The components are manufactured in such a way that fluid creates a suction effect between 90 the head and liner. This constrained acetabular device provides a 110° range of motion and lever-91 out strength of 198 inch-lbs (12). The acetabular liner can be locked into a standard locking 92 mechanism for use in primary and revision acetabular components. A cemented version ( Figure  93 1-B) is available for cementing into a well-fixed acetabular shell of differing locking design, or 94 in cases where the locking mechanism is no longer functioning properly. The cemented version 95 may also be directly cemented to the pelvic bone without any further complementing parts. The head size used with the constrained device is always 36 mm due to the eccentric head mold. 104
The reference group consisted of conventional THAs with 36 mm femoral head size operated 105 during the same time period from 2006 to 2017. The groups were matched by age group (< 49, 106 50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80+ years), sex and diagnosis (primary 107 osteoarthritis, rheumatoid arthritis, other) in a 1:3 ratio, making a total of 1,118 THAs in the 108 reference group (Table 1) 
Statistics 114
Implant survival for the constrained acetabular device and reference groups was calculated from 115 the corresponding cumulative incidence function adjusted for patient death as a competing event 116
for revision for any reason and revision for any aseptic reason as the endpoints. Death of the 117 patient and revision are competing risks in registry studies. Mortality in the constrained 118 acetabular device group as a whole was 51.7% and in the control group 16.3%. Therefore, we 119 used competing risk survivorship analysis instead of Kaplan-Meier survivorship. In a Cox 120 regression model, implant revision hazard ratios (HR) with 95% confidence intervals for any 121 reason for revision were assessed. Implant revision HRs were also assessed separately for 122 revisions performed due to dislocation and for revisions for infection. 123
Including stem fixation in the Cox model as a confounding factor did not change the 124 results, and as stem fixation data was missing from 60 operations in the constrained acetabular 125 device group (16% of all hips in the constrained device group), we decided to exclude it from the 126 model. 127
Revisions were linked to the primary operation through a personal identification number. 128
The The proportional hazards assumption of the Cox models was checked by inspecting the 134 corresponding log-log graphs. For Cox analyses comparing the constrained device group with the 135 reference group, we divided the total follow-up time into three periods (1 to 1.5 years, 1.5 to 3 136 years and the 4th year onwards), as the proportional hazards assumption was not fulfilled for the 137 total follow-up. 138
Inclusion of bilateral cases in a survival analysis violates the basic assumption that all 139 cases are independent. However, several reports have shown that the effect of including bilateral 140 cases in studies of hip and knee implant survival is negligible [13, 14] . Therefore, in this study we 141 included seven patients with a primary constrained acetabular device THA in both hips (14 hips 142 altogether), 43 patients with a conventional THA in both hips (86 hips altogether), and one 143 patient with a constrained device THA in one hip and conventional THA in the other. 144
The Wald test was used to test the estimated hazard ratios. Differences between the 145 groups were considered statistically significant if the p-values were < 0.05 in a two-tailed test. Revision for any reason 154
The 8-year survivorship of the constrained acetabular device group was 94% (CI 91-96) and that 155 of the reference group 93% (CI 89-97) ( Figure 2 ). Overall, there were 21 revisions in the 156 constrained acetabular device group and 49 in the reference group. Reasons for revisions are 157 presented in Table 2 . During the first 1.5 years, the constrained acetabular device group had a 158 similar risk of revision (HR 0.92 (CI 0.48-1.75, p=0.8)) to the reference group. From 1.5 to 3 159 years, the constrained acetabular device group had an increased risk of revision (HR 6.35 (CI 160 1.86-21.7, p=0.003)) over the reference group. From the 4 th year onwards, the constrained 161 acetabular device group had a similar risk of revision (HR 2.02 (CI 0.33-12.44, p=0.4)) to the 162 reference group (Table 3) . 163
164
Revisions due to dislocation 165
The constrained acetabular device group had a similar risk of revision due to dislocation (HR 166 0.27 (CI 0.03-2.05, p=0.2)) compared to the reference group. There was one revision due to 167 dislocation in the constrained acetabular device group and there were 12 in the reference group. 168 169
Revisions due to any aseptic reason (infections excluded) 170
The 8-year survivorship of the constrained acetabular device group was 97% (CI 95-99) and that 171 of the reference group 94% (CI 90-98) with any aseptic revision as the endpoint (Figure 3) . 172 173
Revisions due to infection 174
There were 10 revisions due to infection in the constrained acetabular device group and 11 in the 175 reference group. The constrained acetabular device group had an increased risk of revision due to 176 infection (HR 2.99 (CI 1.27-7.04, p=0.01)) compared to the reference group. However, the 177 mortality was significantly higher in the constrained acetabular device group which indicates that 178 this study group is more fragile than the control group. 179 180 Discussion 181
We found that the 8-year survivorship of the constrained acetabular device group was equal to 182 that of the reference group revision for any reason as the endpoint. There was only one 183 dislocation revision in the constrained acetabular device group compared to 12 in the matched 184 reference group, although the difference between the groups was not statistically significant. 185 There was no difference in the overall revision risk between the constrained acetabular device 186 group and the reference group during the first 1.5 years, when most of the revisions occurred. To 187 our knowledge, this is the first published prospective, register-based cohort study assessing the 188 use of a constrained acetabular device in primary THA. 189
The studied constrained acetabular device was first introduced in low in these earlier single-center studies. Nonetheless, the results of our current study based on 206 high-quality national register data are in line with these previous findings that the constrained 207 acetabular device works well in preventing revision operations in high-risk primary THA 208
patients. 209
We found no difference in overall revision rate between the constrained acetabular device 210 group and the reference group during the first 1.5 years of follow-up, when most (77%) of the 211 revisions occurred. From 1.5 to 3 years postoperatively, the adjusted revision risk of the 212 constrained acetabular device group was higher than in the reference group; the difference is 213 probably attributable to the overall low number of revisions during this time -only 11 out of all 214 70. From the 4 th year onwards, the revision risk returned to being similar between the study 215
groups. 216
There was only one revision for dislocation in the constrained acetabular device group 217 compared to 12 in the matched reference group in the current study. In general, constrained 218 acetabular devices are used for patients with high risk of instability. This indicates that a 219 constrained acetabular device may help to lower the dislocation revision rate compared to 220 conventional primary THA in high dislocation risk patients, even though the difference in 221 dislocation risk between the study groups was not statistically significant. 222 There was no difference in the 8-year survivorship between the two groups after 223 excluding infections as the cause of revision. It has been stated previously that constrained 224 implants may have an increased prevalence of impingement of the femoral neck on the cup, 225 leading to liner damage, locking mechanism failure, dislocation and loosening [10] . We did not 226 find any evidence to support this assumption. Overall, there were only two revisions for aseptic 227 loosening of the cup in the constrained acetabular device group compared to five in the reference 228 group, and the difference was not statistically significant. Patients in the constrained acetabular 229 device group were frailer than those in the reference group, even after matching indicated by the 230 high mortality rate (51.5% vs. 16.3%, respectively). Therefore, one should be cautious in 231 extrapolating our results to younger patients with a longer life expectancy. However, in general 232 these devices are not routinely used in younger and fitter patients. 233
Interestingly, the constrained acetabular device group had a statistically significantly 234 increased risk of revision due to infection compared to the reference group (HR=2.99, p=0.01). 235
We theorized that this is more likely to be associated with patient selection than with the implant 236 itself, as constrained acetabular devices are used in frailer patients at increased risk of infection. 237 Unfortunately, we were not able to adjust the data for comorbidities, which are a well-known 238 risk factor for deep infection [20] . Further, the current approach of including bilateral hip cases 239 may in theory be biased when studying the rate of revision due to infection as there is potentially 240 higher risk of contralateral THA developing PJI when a patient has a current THA with 241 confirmed PJI and potentially septic. However, we think this bias is of theoretical importance 242 only. 243
We acknowledge that our study has several limitations. As with any register research, we 244 were limited to the data the register provides. There are several factors we did not have access to 245 that might have an effect on instability, such as alcoholism, spinal fusion, abductor deficiency, 246 polio, BMI, or dementia. As mentioned earlier, patient selection in regard to constrained 247 acetabular devices tends to lean on more fragile patients. By matching the study groups we were 248 able at least somewhat to reduce these confounding factors. Also, we were not able to assess the 249 patients' radiographs. Furthermore, we were only able to use revision as the outcome. Some of 250 the patients might have suffered pain or had other problems with their implant without having a 251 revision, for example, due to poor general health. Moreover, our results are based on a single 252 constrained acetabular device and are not generalizable to other constrained designs. A strength 253 of our study is the independent population-based cohort design with prospective collection of 254 data and large sample size. The FAR has a high degree of completeness and coverage and 255 thereby provides a representative study population. 256
Conclusion 257
In summary, we found that the 8-year survivorship for the constrained acetabular device 258 group was equal to that of the conventional THA group with revision for any reason as the 259 endpoint. There was only one dislocation revision in the constrained acetabular device group 260 compared to 12 dislocation revisions in the matched reference group, although the difference was 261 not statistically significant. Our current national register-based results indicate that the 262 constrained acetabular device works well in primary THA patients with high instability risk. . Implant survival for the constrained acetabular device and the reference groups with revision for any reason as the endpoint, using patient death as competing risk. 95% CI levels shown around the curves in blue (the reference group) and red (the constrained acetabular device group). Figure 3 . Implant survival for the constrained acetabular device and the reference groups with revision for any mechanical reason as the endpoint (revisions for infection excluded), using patient death as competing risk. 95% CI levels presented around the curves in blue (the reference group) and red (the constrained acetabular device group).
